Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central anxious program, conolidine modulates alternate molecular targets. A Science Innovations study observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://zaneccrfq.digiblogbox.com/62268542/details-fiction-and-conolidin-to-replace-traditional-painkillers